BACKGROUND: Among those accessing treatment, highly active antiretroviral therapy (HAART) has transformed HIV into a chronic and manageable condition. However, high levels of adherence are required to derive a sustained, long-term clinical benefit. The aim of this study was to examine the predictors of adherence based on prescription refill among persons on HAART in British Columbia, Canada. METHODS: This study utilizes data collected between July 2007 and January 2010, as part of the Longitudinal Investigations into Supportive and Ancillary health services (LISA) cohort, which is a study of HIV-positive persons who have accessed antiretroviral therapy (ART) in British Columbia. Participants were considered optimally adherent if they were dispensed ≥95% of their prescribed antiretrovirals. RESULTS: Of a total of 566 participants, only 316 (55.8%) were optimally adherent to HAART. Independent predictors of optimal adherence were increasing age (adjusted odds ratio [AOR] = 1.84, 95% confidence interval [CI]: 1.44-2.33), male gender (AOR = 1.68, 95% CI: 1.07-2.64), and being enrolled in a comprehensive adherence assistance program (AOR = 4.26, 95% CI: 2.12-8.54). Having an annual income <$15 000 (AOR = 0.47, 95% CI: 0.31-0.72) and both former and current injection drug use (AOR = 0.46, 95% CI: 0.29-0.73 and AOR = 0.35, 95% CI: 0.20-0.58, respectively) were independently associated with suboptimal (<95%) adherence. CONCLUSIONS: We found that women and people who inject drugs are at increased risk of being suboptimally adherent to HAART. Optimal adherence remains a significant public health and clinical goal in the context of rapidly expanding access to HAART.
BACKGROUND: Among those accessing treatment, highly active antiretroviral therapy (HAART) has transformed HIV into a chronic and manageable condition. However, high levels of adherence are required to derive a sustained, long-term clinical benefit. The aim of this study was to examine the predictors of adherence based on prescription refill among persons on HAART in British Columbia, Canada. METHODS: This study utilizes data collected between July 2007 and January 2010, as part of the Longitudinal Investigations into Supportive and Ancillary health services (LISA) cohort, which is a study of HIV-positive persons who have accessed antiretroviral therapy (ART) in British Columbia. Participants were considered optimally adherent if they were dispensed ≥95% of their prescribed antiretrovirals. RESULTS: Of a total of 566 participants, only 316 (55.8%) were optimally adherent to HAART. Independent predictors of optimal adherence were increasing age (adjusted odds ratio [AOR] = 1.84, 95% confidence interval [CI]: 1.44-2.33), male gender (AOR = 1.68, 95% CI: 1.07-2.64), and being enrolled in a comprehensive adherence assistance program (AOR = 4.26, 95% CI: 2.12-8.54). Having an annual income <$15 000 (AOR = 0.47, 95% CI: 0.31-0.72) and both former and current injection drug use (AOR = 0.46, 95% CI: 0.29-0.73 and AOR = 0.35, 95% CI: 0.20-0.58, respectively) were independently associated with suboptimal (<95%) adherence. CONCLUSIONS: We found that women and people who inject drugs are at increased risk of being suboptimally adherent to HAART. Optimal adherence remains a significant public health and clinical goal in the context of rapidly expanding access to HAART.
Authors: Putu K Duff; Deborah M Money; Gina S Ogilvie; Florence Ranville; Mary Kestler; Melissa C Braschel; Neora Pick; Kate Shannon Journal: Menopause Date: 2018-05 Impact factor: 2.953
Authors: A Gonzalez-Serna; J E Min; C Woods; D Chan; V D Lima; J S G Montaner; P R Harrigan; L C Swenson Journal: Clin Infect Dis Date: 2014-01-14 Impact factor: 9.079
Authors: Angela A Aidala; Michael G Wilson; Virginia Shubert; David Gogolishvili; Jason Globerman; Sergio Rueda; Anne K Bozack; Maria Caban; Sean B Rourke Journal: Am J Public Health Date: 2015-11-12 Impact factor: 9.308
Authors: Alejandro Gonzalez-Serna; Keith Chan; Benita Yip; William Chau; Rachel McGovern; Hasina Samji; Viviane Dias Lima; Robert S Hogg; Richard Harrigan Journal: J Antimicrob Chemother Date: 2014-04-15 Impact factor: 5.790
Authors: Joëlla W Adams; Brandon D L Marshall; Nur Afiqah Mohd Salleh; Rolando Barrios; Seonaid Nolan; M-J Milloy Journal: Drug Alcohol Depend Date: 2019-10-25 Impact factor: 4.492
Authors: E Jennifer Edelman; Kirsha S Gordon; Janis Glover; Ian R McNicholl; David A Fiellin; Amy C Justice Journal: Drugs Aging Date: 2013-08 Impact factor: 3.923
Authors: Nikoloz Chkhartishvili; Nino Rukhadze; Mariam Svanidze; Lali Sharvadze; Jack A Dehovitz; Tengiz Tsertsvadze; Louise-Anne McNutt; Carlos del Rio Journal: J Int AIDS Soc Date: 2014-04-09 Impact factor: 5.396